HER2-positive breast cancer is a type of breast cancer in which the cancer cells have abnormally high levels of a protein called HER2 (human epidermal growth factor receptor 2) on their surface. This protein normally helps regulate cell growth, but when cells produce too much of it, they divide faster and more aggressively than they should. Roughly 15 to 20 percent of breast cancers are HER2-positive, and while this subtype was once considered especially dangerous, targeted therapies developed over the past two decades have dramatically improved outcomes.
How the HER2 Protein Drives Cancer Growth
HER2 belongs to a family of receptor proteins that sit on the outer membrane of cells and relay signals from outside the cell to its interior. Under normal conditions, these receptors respond to growth factors in the body by triggering carefully controlled cell division, a process essential during development and tissue repair. The problem starts when the HER2 gene is amplified, meaning a cell carries too many copies of it and churns out far more HER2 protein than normal. With excess HER2 receptors studding the cell surface, growth signaling becomes constant and unregulated, pushing the cell down an uncontrolled path of rapid division.
One important detail about HER2-positive tumors: they are deeply dependent on that overactive HER2 signaling to survive. When researchers have blocked HER2 activity in lab and animal studies, tumors shrank. This “addiction” to the HER2 pathway is actually what makes targeted treatments so effective. Shut off the signal the tumor relies on, and it loses its primary engine for growth.
How HER2 Status Is Tested
After a biopsy or surgery, a sample of tumor tissue is sent for a test called immunohistochemistry (IHC), which measures how much HER2 protein is present on the cancer cells. The result is scored on a scale from 0 to 3+. A score of 0 or 1+ is considered HER2-negative. A score of 3+ is HER2-positive. A score of 2+ falls in a gray zone and requires a second test called FISH (fluorescence in situ hybridization), which looks directly at the DNA to count how many copies of the HER2 gene are present. If FISH confirms gene amplification, the cancer is classified as HER2-positive.
Getting accurate HER2 results matters enormously because the entire treatment strategy depends on them. If a tumor is misclassified, a patient could miss out on highly effective targeted therapies or receive them unnecessarily.
The Newer Category: HER2-Low
Until recently, breast cancer was treated as either HER2-positive or HER2-negative, with nothing in between. That changed when researchers recognized a middle ground now called HER2-low, which applies to tumors scoring IHC 1+ or IHC 2+ with a negative FISH result. These cancers don’t have enough HER2 to qualify as positive, but they aren’t completely devoid of it either. This distinction became clinically meaningful after a drug called trastuzumab deruxtecan (brand name Enhertu) showed significant benefit in metastatic HER2-low patients in the DESTINY-Breast04 trial. Patients who would previously have been grouped with the HER2-negative population now have an additional treatment option.
Survival Rates by Stage
HER2-positive breast cancer outcomes have improved substantially with modern targeted therapies. The five-year relative survival rates from the National Cancer Institute’s SEER database (2016 to 2022 data) paint a largely encouraging picture, though they vary by stage and hormone receptor status.
For cancers that are both hormone receptor-positive and HER2-positive (sometimes called “triple positive”):
- Localized (cancer confined to the breast): 99.5%
- Regional (spread to nearby lymph nodes): 91.5%
- Distant (metastatic): 48.7%
For cancers that are hormone receptor-negative and HER2-positive:
- Localized: 97.8%
- Regional: 86.4%
- Distant: 43.1%
The takeaway: when caught at a localized or regional stage, HER2-positive breast cancer has very high survival rates. Even in the metastatic setting, nearly half of patients survive five years or more, a figure that continues to improve as newer treatments become available.
Factors That Affect Recurrence Risk
Not all HER2-positive breast cancers carry the same likelihood of coming back after treatment. A large literature review identified several factors linked to higher recurrence risk. Having two or more positive lymph nodes at diagnosis, a larger primary tumor, and a higher body mass index all increased the chance of recurrence. Interestingly, tumors that are both hormone receptor-positive and HER2-positive were more likely to recur than those that are HER2-positive but hormone receptor-negative.
Response to pre-surgical (neoadjuvant) chemotherapy also matters. Patients who achieve what’s called a pathologic complete response, meaning no cancer is detectable in the tissue removed during surgery, have a significantly lower risk of recurrence. Conversely, having residual cancer after neoadjuvant treatment is one of the strongest predictors that the disease may return.
How HER2-Positive Breast Cancer Is Treated
The backbone of HER2-positive treatment is targeted therapy: drugs specifically designed to block or exploit the HER2 protein. These are typically used in combination with chemotherapy or other targeted agents, and the specific combination depends on the stage and setting.
The most established approach for early-stage disease pairs chemotherapy with trastuzumab (Herceptin), a drug that binds to the HER2 receptor and blocks its signaling while also flagging cancer cells for destruction by the immune system. Pertuzumab (Perjeta) is often added, attacking HER2 from a different angle. For patients who don’t achieve a complete response before surgery, additional targeted therapy may be given afterward to reduce recurrence risk.
For metastatic HER2-positive breast cancer, the treatment landscape has shifted significantly. In December 2025, the FDA approved the combination of trastuzumab deruxtecan (Enhertu) with pertuzumab as a first-line treatment for advanced HER2-positive disease. Enhertu is an antibody-drug conjugate, a type of medication that uses an antibody to seek out HER2-positive cells and deliver a potent chemotherapy payload directly to them, sparing more healthy tissue. In the pivotal trial of over 1,100 patients, this combination extended the median time before the disease progressed to 40.7 months, compared to 26.9 months with the prior standard regimen. The response rate was 87 percent.
These treatments are given as intravenous infusions, typically every three weeks. Side effects can include lowered white blood cell counts and, less commonly, effects on heart function, so patients are monitored with regular blood tests and heart imaging throughout treatment.
Brain Metastases: A Unique Risk
One challenge specific to HER2-positive breast cancer is a higher tendency to spread to the brain. Up to half of patients with metastatic HER2-positive disease develop brain metastases over the course of their illness. At the time of a metastatic diagnosis, about 10.6 percent of HER2-positive patients already have brain or leptomeningeal involvement, roughly double the rate seen in HER2-negative subtypes. The HER2-positive group carries about 2.2 times the odds of brain metastases at metastatic diagnosis compared to HER2-low patients.
This higher risk is thought to be partly because HER2-positive cancer cells have a particular ability to cross the blood-brain barrier, and partly because modern HER2-targeted drugs are so effective at controlling the disease elsewhere in the body that patients live long enough for brain metastases to develop. Newer drug formulations, including some antibody-drug conjugates and small-molecule drugs that can penetrate the brain more effectively, are increasingly being studied and used in this setting.